Additionally, they identify synovial sarcoma and rhabdomyosarcoma—particularly alveolar RMS—as key subtypes that could benefit from CYP2W1-targeted therapies in the future due to the frequent expression of CYP2W1 in these aggressive tumors. This evidence concerns the gene CYP2W1 and synovial sarcoma.